Features lightweight texture with fast penetration
Typical BPC-157 dosage depends on the treatment goal, delivery method, cycle length, and provider guidance
BPC-157 upregulates survival genes (Akt1, KRAS, Src, Foxo1), reduces inflammatory mediators (IL-6, TNF-, NOS2, NFB), scavenges reactive oxygen species through its four carboxylic groups, activates vascular bypass pathways, and maintains blood flow despite vessel occlusion
Data extraction was conducted by two independent reviewers using a standardized form encompassing author details, publication year, study type, employed techniques, number of patients, patient demographics (age), follow-up duration, treatment efficacy outcomes (tumor volume decrease, local pain relief using Visual Analog Scale (VAS), and local pain-free survival, referring to the period during which the patient remains free from pain after the intervention), and AEs graded following the guidelines of the Society of Interventional Radiology (SIR) [13] and the National Cancer Institute Common Terminology Criteria Adverse Events (CTCAE, version 4.0)